he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
详细信息信源地址
编辑: jiang上一页:癫痫病所致的主要病因是啥
下一页:癫痫病怎么治疗
- 2022-05-04小孩子一般几岁会发癫痫病 有哪些显出
- 2022-04-25小儿癫痫早期征状是什么?
- 2022-04-21癫痫发作时的急救方法有
- 2022-04-13Radiology:利用MR颞叶癫痫病灶内侧指纹识别评价的价值
- 2022-04-12心理百科:春节期间小心疾病
- 2022-04-11「痛经」服用止痛药有多大副作用?
- Radiology:利用MR颞叶癫痫病灶内侧指纹识别评价的价值
- 心理百科:春节期间小心疾病
- 「痛经」服用止痛药有多大副作用?
- J Allergy Clin Immunol:IgE对鼻息肉有影响吗?
- 抗癫痫药物预防新发癫痫:任重而道远
- 钙化怎么办?医生提醒:从这两个方面消除,请注意
- 癫痫治疗障碍仍难以克服
- 癫痫猝死:凶手是谁?
- FDA批准Aptiom用于治疗患者癫痫发作
- Autoimmun Rev:心肌炎是一种系统性免疫介导性疾病:发病率、特征和预后
- 过年容易得什么病?
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- 精囊恶性预防 五大保健措施
- 按摩手法 不同的治疗方法
- 不注意这些问题,吃多少药都没用!
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 癫痫治疗 中医治疗癫痫不用担心
- 副作用越多越好
- Alz Res Therapy:健康饮食可以降低痴呆的风险
- FDA警告怀孕期间使用丙戊酸钠药物
- 继发性癫痫能治愈吗 治疗癫痫有几个步骤
- 无精症的表现是什么,如何判断自己是否是无精症患者?
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办?
- 原发性小肠淋巴管扩张症一例
- 癫痫患者手术评估新型工具
- 吃西红柿能预防疾病日常坚持做好这3点,可保护
- JAMA:阳性结果的文章一定更受关注吗?
- 羊癫疯应该用什么方式用药好呢
- 羊癫疯比较好的治疗新方法都有哪些
- 癫痫病怎么治疗才可以皮肤病
- 治疗癫痫病的医务人员
- 二次取栓公共安全吗?看看这个研究研究结果
- 杭州专业治疗癫痫病的医院
- 不同年龄段高血压的病因如何
- 静注药剂或不利于癫痫持续患者预后
- 不伴皮质内侧硬化的皮质癫痫患者隔核增大
- FDA批准开浦兰治疗一个月至4岁癫痫老年人患者
- 哪家癫痫病治疗最出色
- 罕见染病:假显性遗传的B型Kufs染病
- 难治性癫痫持续完全剂该怎么用?